Clinical Trial

Antihypertensive Drug Selection Based on Hemodynamic Phenotypes

Study acronym: HEMOPHENO
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to explore the clinical efficacy and safety of individualized antihypertensive medication guided by hemodynamic phenotyping. The main questions it aims to answer are: 1. Does hemodynamics-based individualized antihypertensive therapy achieve better blood pressure control compared to guideline-based conventional therapy? 2. Does hemodynamics-based individualized therapy have comparable safety to guideline-based conventional treatment? Researchers will compare hemodynamics-based individualized antihypertensive therapy to guideline-based conventional treatment to see if the former is better than the latter. Participants will: 1. Take hemodynamics-based individualized antihypertensive therapy or guideline-based conventional treatment every day for 8 weeks 2. Visit the clinic once every 4 weeks for checkups and tests 3. Keep a diary of their symptoms and any treatment
Trial Details
NCT Number NCT07240909
Lead Sponsor The Third Xiangya Hospital of Central South University
Conditions Hypertension
Enrollment 240 participants
Start Date 2026-01
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-11-21